Overview


This Special Report highlights notable US Food and Drug Administration (FDA) regulations, guidance and enforcement actions in 2016, as well as select developments in product promotion and communication of health care economic information to payors that occurred prior to the start of the Trump administration on January 20, 2017. This report also explores themes in FDA’s 2016 regulatory agenda that may signal the agency’s regulatory priorities in 2017.